{"id":"cepharanthine","rwe":[{"pmid":"41755607","year":"2025","title":"[Development and antiviral activity of cepharanthine nanomicelles].","finding":"","journal":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","studyType":"Clinical Study"},{"pmid":"41755606","year":"2025","title":"[Optimization of cepharanthine solubility and evaluation of its inhibitory activity against coronaviruses].","finding":"","journal":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology","studyType":"Clinical Study"},{"pmid":"41749289","year":"2026","title":"Cepharanthine alleviated chronic prostatitis/chronic pelvic pain syndrome by activating Nrf2 and inhibiting the NF-κB pathway.","finding":"","journal":"Biology direct","studyType":"Clinical Study"},{"pmid":"41747656","year":"2026","title":"Cepharanthine, a valuable sanative alternative for hepatocellular carcinoma through regulating Hippo-Yes-associated protein signal transduction.","finding":"","journal":"Molecular pharmacology","studyType":"Clinical Study"},{"pmid":"41691737","year":"2026","title":"Cepharanthine protects against lipopolysaccharide-induced acute lung injury in mice by blocking NLRP3 inflammasome activation.","finding":"","journal":"International immunopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"5'-AMP-activated protein kinase catalytic subunit alpha-1","category":"target"},{"label":"PRKAA1","category":"gene"},{"label":"NFKB1","category":"gene"},{"label":"Active","category":"status"},{"label":"Alopecia","category":"indication"},{"label":"Aptyalism","category":"indication"},{"label":"Leukopenia","category":"indication"},{"label":"Snake bite - wound","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Phytogenic","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"},{"label":"Radiation-Protective Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEPHARANTHINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:17:34.387311+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:17:40.179768+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHARANTHINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:17:40.697041+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL449782/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:17:41.422854+00:00"}},"allNames":"cepharanthin","offLabel":[],"synonyms":["cepharanthine","cepharanthin"],"timeline":[{"date":"1951-01-01","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"1951-01-01","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Cepharanthin","ecosystem":[{"indication":"Alopecia","otherDrugs":[{"name":"minoxidil","slug":"minoxidil","company":""}],"globalPrevalence":null},{"indication":"Aptyalism","otherDrugs":[{"name":"pilocarpine","slug":"pilocarpine","company":""}],"globalPrevalence":null},{"indication":"Leukopenia","otherDrugs":[],"globalPrevalence":null},{"indication":"Snake bite - wound","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"5'-AMP-activated protein kinase catalytic subunit alpha-1","targets":[{"gene":"PRKAA1","source":"DrugCentral","target":"5'-AMP-activated protein kinase catalytic subunit alpha-1","protein":"5'-AMP-activated protein kinase catalytic subunit alpha-1"},{"gene":"NFKB1","source":"DrugCentral","target":"Nuclear factor NF-kappa-B p105 subunit","protein":"Nuclear factor NF-kappa-B p105 subunit"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Cepharanthin targets the 5'-AMP-activated protein kinase catalytic subunit alpha-1 (AMPKα1), a key enzyme in the AMPK signaling pathway, which regulates cellular energy homeostasis and metabolism."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5375","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEPHARANTHINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEPHARANTHINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:30:12.881700","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:43.098668+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chlorhexidine","drugSlug":"chlorhexidine","fdaApproval":"1976-09-17","patentExpiry":"Oct 2, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"clomipramine","drugSlug":"clomipramine","fdaApproval":"1989-12-29","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"fluphenazine","drugSlug":"fluphenazine","fdaApproval":"1959-09-09","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"menadione","drugSlug":"menadione","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"promazine","drugSlug":"promazine","fdaApproval":"1956-04-13","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"trifluoperazine","drugSlug":"trifluoperazine","fdaApproval":"1959-04-16","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"triflupromazine","drugSlug":"triflupromazine","fdaApproval":"1957-09-16","patentStatus":"Unknown","relationship":"same-target"}],"genericName":"cepharanthine","indications":{"approved":[{"name":"Alopecia","source":"DrugCentral","snomedId":56317004,"regulator":"FDA"},{"name":"Aptyalism","source":"DrugCentral","snomedId":87715008,"regulator":"FDA"},{"name":"Leukopenia","source":"DrugCentral","snomedId":84828003,"regulator":"FDA"},{"name":"Snake bite - wound","source":"DrugCentral","snomedId":283840005,"regulator":"FDA"}],"offLabel":[{"name":"Coronavirus infection","source":"DrugCentral","drugName":"CEPHARANTHINE","evidenceCount":43,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"chlorhexidine","brandName":"chlorhexidine","genericName":"chlorhexidine","approvalYear":"1976","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"},{"drugId":"clomipramine","brandName":"clomipramine","genericName":"clomipramine","approvalYear":"1989","relationship":"same-target"},{"drugId":"fluphenazine","brandName":"fluphenazine","genericName":"fluphenazine","approvalYear":"1959","relationship":"same-target"},{"drugId":"menadione","brandName":"menadione","genericName":"menadione","approvalYear":"","relationship":"same-target"},{"drugId":"promazine","brandName":"promazine","genericName":"promazine","approvalYear":"1956","relationship":"same-target"},{"drugId":"trifluoperazine","brandName":"trifluoperazine","genericName":"trifluoperazine","approvalYear":"1959","relationship":"same-target"},{"drugId":"triflupromazine","brandName":"triflupromazine","genericName":"triflupromazine","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05398705","phase":"PHASE2","title":"Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2022-05-31","conditions":["Asymptomatic COVID-19"],"enrollment":450,"completionDate":"2022-08-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7592YJ0J6T","CHEBI":"CHEBI:3546","UMLSCUI":"C0055082","chemblId":"CHEMBL449782","ChEMBL_ID":"CHEMBL449782","KEGG_DRUG":"D01035","DRUGBANK_ID":"DB16824","PUBCHEM_CID":"10206","MESH_SUPPLEMENTAL_RECORD_UI":"C006947"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":458,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 24","pmid":"41755607","title":"[Development and antiviral activity of cepharanthine nanomicelles].","journal":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology"},{"date":"2025 Jul 17","pmid":"41755606","title":"[Optimization of cepharanthine solubility and evaluation of its inhibitory activity against coronaviruses].","journal":"Sheng wu gong cheng xue bao = Chinese journal of biotechnology"},{"date":"2026 Feb 26","pmid":"41749289","title":"Cepharanthine alleviated chronic prostatitis/chronic pelvic pain syndrome by activating Nrf2 and inhibiting the NF-κB pathway.","journal":"Biology direct"},{"date":"2026 Mar","pmid":"41747656","title":"Cepharanthine, a valuable sanative alternative for hepatocellular carcinoma through regulating Hippo-Yes-associated protein signal transduction.","journal":"Molecular pharmacology"},{"date":"2026 Apr 1","pmid":"41691737","title":"Cepharanthine protects against lipopolysaccharide-induced acute lung injury in mice by blocking NLRP3 inflammasome activation.","journal":"International immunopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"1951-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:17:43.098668+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}